Source: BioPortfolio

Transcriptic: With $80M ReCode Looks to Advance RNA Therapies for Lung Diseases

Two companies working on treatments for rare genetic lung diseases have combined efforts and raised $80 million to bring into human testing next year two investigational treatments that use types of RNA to tweak mutated proteins. Dallas company ReCode Ther...

Read full article »
Est. Annual Revenue
$5.0-25M
Est. Employees
25-100
Yvonne Linney's photo - CEO of Transcriptic

CEO

Yvonne Linney

CEO Approval Rating

81/100

Read more